These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30207910)

  • 21. The pharmaceutical industry--prices and progress.
    Scherer FM
    N Engl J Med; 2004 Aug; 351(9):927-32. PubMed ID: 15329432
    [No Abstract]   [Full Text] [Related]  

  • 22. Providing health economic data to managed care.
    Navarro RP
    Manag Care Interface; 1998 Sep; 11(9):62-3, 66. PubMed ID: 10187588
    [No Abstract]   [Full Text] [Related]  

  • 23. The response to health care reform by the pharmaceutical industry.
    Krulwich AS
    Food Drug Law J; 1995; 50(1):1-22. PubMed ID: 10342983
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2010 Jan; ():1-19. PubMed ID: 20213917
    [No Abstract]   [Full Text] [Related]  

  • 25. Medicaid drug bill mandates pharmaceutical discounts.
    Blankenship N
    Provider; 1991 Jan; 17(1):45. PubMed ID: 10108564
    [No Abstract]   [Full Text] [Related]  

  • 26. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
    Werling K; Abraham S; Strelec J
    J Health Care Finance; 2007; 34(2):57-70. PubMed ID: 18972994
    [No Abstract]   [Full Text] [Related]  

  • 27. Medicare should bargain for lower drug prices, study says.
    Med Health; 2005 Oct; 59(36):1, 3, 7. PubMed ID: 16240494
    [No Abstract]   [Full Text] [Related]  

  • 28. The reimbursement factor in pharmaceutical regulation: rebates, cost-effectiveness, and practice guidelines.
    Shulman SR
    Pharmacoeconomics; 1992; 1(Suppl 1):21-7. PubMed ID: 10146927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trying to get control of drug costs, Florida earns kudos--and a lawsuit.
    Carlson B
    Manag Care; 2001 Oct; 10(10):17, 21. PubMed ID: 11764743
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmaceuticals and medical devices: business practices. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-36. PubMed ID: 23297448
    [No Abstract]   [Full Text] [Related]  

  • 31. Federal drug discount program proves tricky for hospitals to navigate.
    Thompson CA
    Am J Health Syst Pharm; 2000 Dec; 57(23):2130, 2134, 2139-40. PubMed ID: 11127690
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmaceutical costs. An overview and analysis of legal and policy responses by the states.
    Latham SR
    J Leg Med; 2003 Jun; 24(2):141-73. PubMed ID: 12775406
    [No Abstract]   [Full Text] [Related]  

  • 33. Estimates of the Number of Brand-name Drugs Affected by the Medicaid Rebate Cap in 2017.
    Dickson S
    JAMA Intern Med; 2019 Mar; 179(3):437-439. PubMed ID: 30667469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medicare Part D: how do vulnerable beneficiaries fare?
    Summer L; Nemore P; Finberg J
    Issue Brief (Commonw Fund); 2008 Apr; 35():1-11. PubMed ID: 18536146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Price controls and global pharmaceutical progress.
    Scherer FM
    Health Aff (Millwood); 2009; 28(1):w161-4. PubMed ID: 19088103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Good law from tragic facts--Congress, the FDA, and preemption.
    Annas GJ
    N Engl J Med; 2009 Sep; 361(12):1206-11. PubMed ID: 19759383
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmaceuticals and medical devices: cost savings. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2008 Jan; ():1-27. PubMed ID: 18345555
    [No Abstract]   [Full Text] [Related]  

  • 38. The FDA and the pharmaceutical industry: is regulation contributing to drug shortage?
    Roman A
    Albany Law Rev; 2013-2014; 77(2):539-77. PubMed ID: 24851322
    [No Abstract]   [Full Text] [Related]  

  • 39. Medicare Part D: successes and continuing challenges. Impact of Medicare Part D on Massachusetts health programs and beneficiaries.
    Thomas CP; Sussman J; ;
    Issue Brief (Mass Health Policy Forum); 2007 May; (32):1-32. PubMed ID: 17546802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health Insurance and Coverage of Evidence-Based Care.
    Rosenbaum S
    Public Health Rep; 2017; 132(2):260-263. PubMed ID: 28135426
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.